Search research articles
Contact Us
Filters
Showing results (11-20 of 40) with videos related to
Page
of 4
Sort By:
VASA. Supplementum
|
January 1, 1992
[Prostaglandin E1 in intermittent claudication]
P Scheffler, D de la Hamette, W Rogatti
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
September 1, 1991
On the metabolism of prostaglandin E1 administered intravenously to human volunteers
B A Peskar, W Cawello, W Rogatti, et al.
Lancet (London, England)
|
July 19, 1986
Prostaglandin E1 decreases activation of arterial smooth-muscle cells
H Sinzinger, P Fitscha, O Wagner, et al.
European Journal of Clinical Pharmacology
|
January 1, 1996
Prostaglandin E1 increases binding of 123I-low-density lipoprotein to the human liver in vivo
H Sinzinger, H Kritz, I Virgolini, et al.
Wiener Klinische Wochenschrift
|
January 1, 1994
[The effectiveness of standardized exercise training in intermittent claudication]
M Cachovan, P Scheffler, J Gruss, et al.
Agents and Actions. Supplements
|
January 1, 1992
Prostaglandin (PG) E1 and 13,14-dihydro (DH) PGE1 are diminishing radiation-induced arterial damage
I Neumann, W Rogatti, I Virgolini, et al.
Thrombosis Research
|
May 15, 1991
Interaction between prostaglandin E1 and nitric oxide (NO)
R Katzenschlager, K Weiss, W Rogatti, et al.
Prostaglandins
|
January 1, 1996
Prostaglandin E1 decreases circulating endothelial cells
H Sinzinger, P Fitscha, H Kritz, et al.
Prostaglandins & Other Lipid Mediators
|
July 8, 1998
Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance
H Sinzinger, I Neumann, J O'Grady, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|
April 1, 1997
PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion technique
H Sinzinger, I Neumann, J O'Grady, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 40) with videos related to
Sort By:
Page
of 4
VASA. Supplementum
|
January 1, 1992
[Prostaglandin E1 in intermittent claudication]
P Scheffler, D de la Hamette, W Rogatti
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
September 1, 1991
On the metabolism of prostaglandin E1 administered intravenously to human volunteers
B A Peskar, W Cawello, W Rogatti, et al.
Lancet (London, England)
|
July 19, 1986
Prostaglandin E1 decreases activation of arterial smooth-muscle cells
H Sinzinger, P Fitscha, O Wagner, et al.
European Journal of Clinical Pharmacology
|
January 1, 1996
Prostaglandin E1 increases binding of 123I-low-density lipoprotein to the human liver in vivo
H Sinzinger, H Kritz, I Virgolini, et al.
Wiener Klinische Wochenschrift
|
January 1, 1994
[The effectiveness of standardized exercise training in intermittent claudication]
M Cachovan, P Scheffler, J Gruss, et al.
Agents and Actions. Supplements
|
January 1, 1992
Prostaglandin (PG) E1 and 13,14-dihydro (DH) PGE1 are diminishing radiation-induced arterial damage
I Neumann, W Rogatti, I Virgolini, et al.
Thrombosis Research
|
May 15, 1991
Interaction between prostaglandin E1 and nitric oxide (NO)
R Katzenschlager, K Weiss, W Rogatti, et al.
Prostaglandins
|
January 1, 1996
Prostaglandin E1 decreases circulating endothelial cells
H Sinzinger, P Fitscha, H Kritz, et al.
Prostaglandins & Other Lipid Mediators
|
July 8, 1998
Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance
H Sinzinger, I Neumann, J O'Grady, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|
April 1, 1997
PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion technique
H Sinzinger, I Neumann, J O'Grady, et al.
Page
of 4